New cancer treatment trial targets multiple advanced tumors
Disease control
Completed
This study tested a new immunotherapy combination (ICT01 plus low-dose IL-2) for people with advanced solid tumors that had stopped responding to standard treatments. The trial aimed to determine if this combination was safe and could help control cancer growth. It involved 56 pa…
Phase: PHASE1, PHASE2 • Sponsor: ImCheck Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC